Kilambi News
Friday, November 20, 2026

Archive

Every story, newest first.

Wednesday, November 11, 2026

Politics

World leaders open COP31 summit in Antalya

World leaders began two days of speeches at the COP31 Antalya Leaders Summit on Wednesday, with Turkey pushing an electrification goal and the United States absent for the second year in a row.

Politics

Van Hollen challenges Schumer for Senate leader

Chris Van Hollen's challenge to Chuck Schumer for Senate majority leader drew formal endorsements from Bernie Sanders and Senator-elect Abdul El-Sayed on Thursday, while Schumer said he has the votes to win the December 1 secret ballot.

Politics

UNICEF warns long range drones are remaking Sudan war

UNICEF said on Tuesday that drones travelling up to 1,500 kilometres struck Sudanese power stations on every day of the last week of October, with up to 15 hit in the month, and that armed drones account for two in three child casualties in Sudan this year.

Life Sciences

Scholar Rock sells review voucher for 205 million dollars

Scholar Rock has agreed to sell the Priority Review Voucher it won with the September approval of Isembyld for 205 million dollars, while its first patients were infused in October and third quarter product revenue came in at 0.6 million dollars.

Life Sciences

Mirum hepatitis D antibody clears second Phase 3 trial

Mirum's brelovitug met the combined primary endpoint in the Phase 3 AZURE-4 study of chronic hepatitis D, with 59 percent of patients on the weekly dose and 44 percent on the monthly dose achieving virologic response with ALT normalisation at week 24, against none on delayed treatment.

Life Sciences

Life sciences also notable: Coherus cuts, Vertex layoffs, Lilly suit

Coherus is cutting about 30 percent of its workforce to focus on esophageal cancer, Vertex will lay off 78 Crinetics staff in San Diego in January, and a former Lilly sales manager has sued over alleged off-label Mounjaro promotion.

Life Sciences

FDA approves Pimjetmi for tenosynovial giant cell tumor

The FDA has approved pimicotinib, sold as Pimjetmi, for adults with symptomatic tenosynovial giant cell tumor where surgery could worsen function, after the drug produced a 56 percent response rate against 3 percent on placebo at week 25.

Life Sciences

Dutch regulator probes Biogen over Stratify test access

The Netherlands Authority for Consumers and Markets is investigating whether Biogen abused a dominant position by making its Stratify blood test available only to patients on, or considering, its multiple sclerosis drug Tysabri.

Life Sciences

Democrats demand unredacted Trump drug pricing deal documents

Incoming Democratic committee chairs have sent a new round of letters to 27 drugmakers demanding the unredacted text of their most-favored-nation pricing agreements with the Trump administration, according to STAT.

Life Sciences

Beam base editing therapy meets pivotal sickle cell endpoint

Beam Therapeutics said its one-time base-edited cell therapy risto-cel met the primary endpoint of the BEACON trial, freedom from severe vaso-occlusive crises for at least 12 consecutive months, and that it plans a United States approval filing as early as the end of 2026.